Global Biochip Markets: Microarrays and Lab-on-a-Chip

Home
Biotechnology
Global Biochip Markets: Microarrays and Lab-on-a-Chip

Global Biochip Markets: Microarrays and Lab-on-a-Chip

Price:

USD $4,850.00

ISBN/SKU #:

GB-BIO049C

Research Group:

BCC

Date of Publication:

January 2010

Summary

The goal for Biochip Markets: Microarrays and Lab-on-a-Chip study was to determine the status of current and emerging biochip technologies and products, and assess their worldwide growth potential over a 5-year period from 2009 to 2014. We were particularly interested in characterizing the biochip markets for single nucleotide polymorphisms (SNPs), epigenetics, array comparative genome hybridization (aCGH), microRNA (miRNA), proteomics microarray, and lab-on-a-chip (LOAC) markets, which will provide substantial future growth opportunities for biochips. A particular focus of this study is the market for biochip-based diagnostics products. Our key objective was to present a comprehensive discussion of where the state-of-the-art is in biochip technologies and the current and future commercial potential for each of the key market segments.

Biology is following a path that is reminiscent of the early electronics industry: a miniaturization and large-scale integration process that will revolutionize life-science research, drug discovery and development, medical diagnostics and biotechnology. The ongoing miniaturization and large-scale integration process is encompassed in devices known as biochips, including microarrays and LOAC microfluidic devices. Biochips represent a diverse group of nanotechnologies that can be expected to exert a significant impact in life-science research, diagnostics, and medicine. DNA microarrays are already an established technology generating substantial revenue derived from gene expression, SNP analysis and gene resequencing. Several biochip-based diagnostics have been launched in the past few years, including some that have been approved by the FDA for in vitro diagnostic (IVD) applications. We foresee significant market growth in biochips as diagnostics. Protein microarrays are gaining prominence in the marketplace, while future, emerging array technologies, including tissue/cell and glycomics arrays, are increasing in importance. LOAC devices are also making rapid progress in important pharmaceutical and diagnostics market segments. Given the rapidly advancing bio- and nanotechnologies associated with this business, and the changing industry dynamics, it is timely to reexamine the biochips business.

We have compiled a study of critical biochip technologies that will be important in the four major end-user segments. We present the biochip technologies and growth driving forces, product types, key market applications, companies, and alliances, future market potential and product sales forecasts for the period 2009 through 2014. We project the future use of microarray and LOAC products for the key end-use segments: research tools, drug discovery and development, diagnostics, next-generation sequencing, biodefense, food testing, and forensics. This study will be of particular interest to the companies in the following industries: diagnostics, pharmaceuticals, biotechnology, nanotechnology, life-sciences tools, biodefense, medical devices, polymers, glass, bioinformatics, and genetic services. It will also be of interest to companies involved in drug and/or biomarker discovery programs, manufacturers of microarrays and LOAC devices, antibodies, restriction enzymes or primers, bioinformatics developers, and cancer researchers and clinicians.

The study scope includes the major biochip technologies that are likely to become commercialized within the next 5 years. Each technology is analyzed to determine its market status, impact on future market segments, and forecast growth from 2009 through 2014. Technology issues and market driving forces are discussed. Influencing factors including large-scale integration, microfluidics, nanotechnology, large-scale biochip, genomic and proteomic research initiatives, cancer diagnostic and treatment trends, and drug discovery and development needs are discussed. This report presents an analysis of each of the key market segments that will be commercially important during the next 5 years: research tools, drug discovery and development, diagnostics, next-generation DNA sequencing, biodefense, food safety, and forensics. Based on our analysis, we evaluate the potential applications of biochips in each of the major market segments, and forecast sales revenues for 2009 through 2014. This report examines biochip companies and industry alliances, and the impact of large-scale biochip-related projects on the market growth. We also examine patent strategies within the industry. A total of 143 companies are profiled.

THIS REPORT:

The total market for biochips was $2.4 billion in 2008 which increased to $2.6 billion in 2009. This is expected to grow at compound annual growth rate (CAGR) of 17.7% to reach $5.9 billion by 2014
The DNA microarrays market was nearly $1.2 billion in 2008; this further increased to $1.3 billion in 2009, this projected to reach $2.7 billion in 2014, for a 5-year CAGR of 15.2%.
Sales in the LOAC market amounted to $755 million in 2008 which increased to $817 million in 2009. This is projected to increase to $2.1 billion in 2014, for a 5-year CAGR of 20.9%.

TABLE OF CONTENTS

Chapter- 1: INTRODUCTION

STUDY GOALS AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	1
INTENDED AUDIENCE	2
SCOPE OF REPORT	2
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYST CREDENTIALS	3
DISCLAIMER	4

Chapter-2: SUMMARY

SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS)	5
SUMMARY FIGURE GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, 2007-2014 ($ MILLIONS)	6

Chapter-3: OVERVIEW

INTRODUCTION	8
TABLE 1 BIOLOGY DOWNSIZING REVOLUTION	10
FIGURE 1 EVOLUTION OF BIOCHIPS	10
BIOCHIP TYPES	12
FIGURE 2 CLASSIFICATION OF BIOCHIPS	12
TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES	13
TABLE 3 BIOCHIP NOMENCLATURE	15
BIOCHIP TECHNOLOGIES COVERED IN THIS REPORT	16
TABLE 4 SCOPE OF THIS REPORT	16
WHAT IS NEW IN THIS REPORT	16
MARKET POTENTIAL OF BIOCHIPS	17
TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS)	18
TABLE 6 GLOBAL VALUE OF BIOCHIP MARKET BY END USE, THROUGH 2014 ($ MILLIONS)	18
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS	19
TABLE 7 PRIMARY FORCES DRIVING OVERALL BIOCHIPS GROWTH	20
BIOCHIPS: A CONVERGENCE OF DIVERSE TECHNOLOGIES	22
TABLE 8 MULTIDISCIPLINARY FIELD OF BIOCHIPS	22
LIFE CYCLE STATUS OF BIOCHIP PRODUCTS	23
TABLE 9 LIFE CYCLE STATUS OF BIOCHIP TYPES	23
COMMERCIAL STATUS OF BIOCHIPS	24
MICROARRAYS	24
LOAC	25
THE BIOCHIP INDUSTRY	25
TABLE 10 BIOCHIP INDUSTRY KEY COMPETITORS	25

Chapter-4: MICROARRAY TECHNOLOGIES

INTRODUCTION	27
THE NANOSCALE WORLD	27
TABLE 11 THE NANOSCALE WORLD	27
TABLE 12 MICROARRAY TYPES	28
TABLE 13 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES	28
DNA MICROARRAY TECHNOLOGIES	30
INTRODUCTION	30
FIGURE 3 MICROARRAY FEATURE DENSITY	30
FIGURE 4 MICROARRAY RESOLUTION	31
TABLE 14 MICROARRAY GENOME CONTENT	31
TABLE 15 DNA MICROARRAY PLATFORM FEATURES	32
TABLE 16 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS	33
STEPS IN THE DNA MICROARRAY EXPERIMENT	36
DNA MICROARRAY APPLICATIONS	36
TABLE 17 DNA MICROARRAY APPLICATIONS	37
Gene Expression Profiling	38
TABLE 18 PROBES FOR GENE EXPRESSION DNA MICROARRAYS	38
TABLE 19 EXAMPLE APPLICATIONS OF GENE EXPRESSION PROFILING	40
FIGURE 5 GENETIC ANALYSIS TECHNOLOGY COMPETITIVE SPACE	41
TABLE 20 GENETIC ANALYSIS TECHNOLOGIES COMPARISON	42
FIGURE 6 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1	43
FIGURE 7 COMPETITIVE SPACE FOR GENE EXPRESSION ANALYSIS	44
FIGURE 8 APPLICATIONS SPACE WITH INTENSE TECHNOLOGY COMPETITION	45
TABLE 21 PLATFORMS FOR HIGH-THROUGHPUT QUANTITATIVE GENE EXPRESSION ANALYSIS	47
TABLE 22 GENE EXPRESSION PLATFORMS OF TWO LEADING DNA ARRAY MANUFACTURERS	47
TABLE 23 PROBE SENSITIVITY AND SPECIFICITY	48
SNP Analysis	50
FIGURE 9 SNP ANALYSIS PLATFORMS	51
Epigenetic Analysis	52
FIGURE 10 EPIGENOMICS WITHIN THE MOLECULAR BIOLOGY PARADIGM	53
DNA Methylation	53
FIGURE 11 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION	54
Histones	54
FIGURE 12 HISTONE TAIL REGIONS MODIFIED BY HAT AND HDAC	55
DNA Methylation and Histone Analysis Workflow	56
FIGURE 13 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS	57
DNA Methylation Microarrays	57
ChIP-on-Chip	58
TABLE 24 CHIP ASSAYS	59
TABLE 25 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES	60
TABLE 26 PLATFORMS FOR HIGH DENSITY OLIGONUCLEOTIDE EPIGENETICS ARRAYS	61
Cytogenetic Analysis	61
TABLE 27 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES	62
FIGURE 14 COMPETITIVE SPACE FOR CNV ANALYSIS	63
TABLE 28 CGH MICROARRAY PROBE PLATFORMS	65
TABLE 29 CGH MICROARRAY TRENDS	66
TABLE 30 FUTURE TECHNOLOGY NEEDS FOR CGH MICROARRAYS	68
miRNA Analysis	69
TABLE 31 WORKFLOW FOR AN MIRNA EXPERIMENT	70
TABLE 32 TECHNICAL CHALLENGES FOR MIRNAS	71
ARRAYS ON BEADS	72
TABLE 33 ARRAYS ON BEADS VERSUS PLANAR MICROARRAYS	72
CATALOG AND CUSTOM DNA MICROARRAYS	72
SUPPLY OF REAGENTS AND SAMPLE PREPARATION FOR MICROARRAYS	73
TOXICOGENOMICS	74
DNA SEQUENCING	75
FIGURE 15 COMPARISON OF SANGER WITH UHTS DNA SEQUENCING TECHNOLOGIES	76
TABLE 34 SMS TECHNOLOGY	77
TABLE 35 COMPARISON OF SELECTED DNA SEQUENCING PLATFORMS	78
FIGURE 16 COMPETITIVE SPACE FOR HIGH-THROUGHPUT GENOMIC ANALYSIS	79
TABLE 36 BIOCHIP CONTENT IN NHGRI GRANTEES FOR NEXT-GENERATION DNA SEQUENCING, 2005	80
TABLE 37 NEXT-GENERATION DNA SEQUENCING COMPANIES	82
RESEQUENCING APPROACHES IN DIAGNOSTICS	82
DNA MICROARRAY MANUFACTURING	83
FIGURE 17 DNA MICROARRAY MANUFACTURING TECHNOLOGIES	83
TABLE 38 DNA MICROARRAY PROBE DENSITY TRENDS, FEATURES PER CHIP, 1996�2009	85
DNA MICROARRAY TECHNOLOGY TRENDS	85
DNA MICROARRAY TECHNOLOGY CHALLENGES	86
FIGURE 18 DNA MICROARRAY COST-VOLUME CURVE	87
PROTEIN MICROARRAY TECHNOLOGIES	88
INTRODUCTION	88
FIGURE 19 IMPORTANCE OF PROTEINS	88
PROTEOMICS WORKFLOW	89
FIGURE 20 PROTEIN ANALYSIS APPROACHES CONTRASTED	89
PROTEIN MICROARRAY DESIGN FEATURES	90
TABLE 39 PROTEIN MICROARRAY PLATFORMS	90
PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS	91
TABLE 40 PROTEIN MICROARRAYS AS RESEARCH TOOLS	92
PROTEIN MICROARRAY TYPES	93
TABLE 41 PROTEIN MICROARRAY PRODUCT TYPES	93
PROTEIN MICROARRAY TECHNOLOGY CHALLENGES	95
TABLE 42 PROTEIN MICROARRAY TECHNICAL CHALLENGES	96
PROTEIN MICROARRAY TECHNOLOGY TRENDS	98
TABLE 43 PROTEIN MICROARRAY TECHNOLOGY TRENDS	98
EMERGING MICROARRAY TECHNOLOGIES	99
TABLE 44 EMERGING MICROARRAY TECHNOLOGIES	99
GLYCOMICS MICROARRAYS	100
TMAS	102
FCMS	103
TABLE 45 U.S. GOVERNMENT INITIATIVES PROMOTING EMERGING MICROARRAYS	104
MICROARRAY TECHNOLOGY TRENDS	105
TABLE 46 MICROARRAY TECHNOLOGY TRENDS	105

Chapter-5: LOAC TECHNOLOGIES

INTRODUCTION	107
TABLE 47 MICROFLUIDICS PRODUCT LIFE CYCLE STAGE	107
TABLE 48 LOAC SUBSTRATE TECHNOLOGIES	108
LOAC TYPES	109
TABLE 49 LOAC TYPES	109
IN VITRO PROTEOMICS	109
ELECTROPHORESIS ON A CHIP	110
STRUCTURAL PROTEOMICS	110
PCR ON A CHIP	111
IMMUNOASSAYS ON A CHIP	112
TABLE 50 IMMUNOASSAY-ON-A-CHIP APPLICATIONS	114
LOAC APPLICATIONS	114
TABLE 51 LOAC MARKET SEGMENTS	115
TABLE 52 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS	116
LOAC KEY TECHNOLOGY TRENDS	116
TABLE 53 LOAC KEY TECHNOLOGY TRENDS	117
TABLE 54 LOAC TECHNOLOGY PLATFORMS	118
LOAC TECHNOLOGY CHALLENGES	119
TABLE 55 LOAC TECHNOLOGY CHALLENGES	120

Chapter-6: BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT

BIOCHIP MARKET SEGMENTATION	121
TABLE 56 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS	121
DRUG DISCOVERY AND DEVELOPMENT	122
TABLE 57 DRUG R&D INVESTMENT BY STAGE, 2003 (%)	123
DRUG INDUSTRY CHALLENGES	123
OVERVIEW OF THE DRUG DISCOVERY AND DEVELOPMENT PROCESS	124
FIGURE 21 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE	124
TABLE 58 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	125
DRUG TARGET IDENTIFICATION	127
DRUG DISCOVERY	127
Structural Biology	127
Lead Generation	128
Lead Optimization	131
Process R&D	132
Preclinical and Clinical Trials	132
NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS	132
TABLE 59 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT	132
FIGURE 22 VALIDATION GAP FOR FUTURE DRUG TARGETS (NUMBER OF POTENTIAL DRUG TARGETS)	135

Chapter-7: BIOCHIP APPLICATIONS IN DIAGNOSTICS

INTRODUCTION	137
DRIVING FORCES FOR ADOPTION OF BIOCHIP DIAGNOSTIC PLATFORMS	137
BIOMARKER DISCOVERY AND VALIDATION	137
CLINICAL ACCEPTANCE OF BIOMARKER-BASED TESTS	138
TABLE 60 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS	139
MICROARRAY STANDARDIZATION EFFORTS	140
Microarray Quality Control Project	140
External RNA Controls Consortium (ERCC) Study	141
Association of Bimolecular Resource Facilities (ABRF) CGH Microarray Platform Study	142
TABLE 61 COMPARISON OF ARRAY-CGH PLATFORMS	142
OVERVIEW OF MDX	143
INTRODUCTION	143
BENEFITS OF BIOCHIPS AS AN MDX PLATFORM	144
FIGURE 23 BIOCHIPS TARGET HIGH GROWTH, HIGH MARGIN PORTION OF THE IVD MARKET	146
TABLE 62 BIOTECHNOLOGY DRUGS APPROVED BY THE FDA, 1980�2008 (NUMBER)	147
PHARMACOGENOMICS TESTS	147
STRATEGIES FOR COMMERCIALIZING PGX TESTS	149
MDX MARKET PENETRATION CHALLENGES	150
TABLE 63 COMPARISON OF DNA-BASED MDX PLATFORMS	151
TABLE 64 FACTORS AFFECTING PENETRATION OF BIOCHIPS INTO THE MDX MARKET	152
MDX MARKET SEGMENTS	154
MDX TEST SENSITIVITY AND SPECIFICITY	155
FIGURE 24 SENSITIVITY AND SPECIFICITY	156
STATUS OF BIOCHIPS DIAGNOSTICS BY INDICATION	157
SUMMARY OF BIOCHIPS DIAGNOSTICS	157
CANCER OVERVIEW	157
TABLE 65 U.S. INCIDENCE AND TREATMENT DECISIONS FOR SELECTED CANCERS, 2009	157
HEMATOLOGICAL CANCERS	158
BLADDER CANCER	158
BREAST CANCER	159
Breast Cancer Screening	159
Prognosis and Pharmacogenetics Tests	160
FIGURE 25 BREAST CANCER TREATMENT DECISION TREE FOR ONCOTYPE DX	161
TABLE 66 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION	162
Breast Cancer MDx Platforms	162
TABLE 67 BREAST CANCER MDX TECHNOLOGY PLATFORMS	163
Breast Cancer Multivariate Diagnostic Tests	164
TABLE 68 COMMERCIAL LANDSCAPE FOR MULTIVARIATE BREAST CANCER TESTS, BY PARAMETER	164
Regulatory Status of Gene Profiling Diagnostic Tests	167
TABLE 69 FDA REGULATORY POSITION ON IVDMIA	167
CERVICAL CANCER	168
TABLE 70 COMMERCIAL LANDSCAPE FOR HPV TESTS	168
COLORECTAL CANCER	170
Conventional Colorectal Cancer Screening Tests	170
TABLE 71 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER	171
Molecular Colorectal Cancer Diagnostics Tests	172
TABLE 72 COMMERCIAL LANDSCAPE FOR COLORECTAL MOLECULAR TESTS	172
CUP	174
TABLE 73 COMMERCIAL MDX PLATFORMS FOR TISSUE OF ORIGIN TESTS	175
GASTRIC CANCER	176
LUNG CANCER	177
OVARIAN CANCER	179
TABLE 74 OVARIAN CANCER SCREENING TESTS	179
TABLE 75 OVARIAN CANCER DIAGNOSTIC TEST STATUS	180
PANCREATIC CANCER	180
PEDIATRIC CANCERS	181
PROSTATE CANCER	181
COMPREHENSIVE CANCER TESTS	183
STATUS OF BIOCHIP-BASED INFECTIOUS DISEASE DIAGNOSTICS	183
SEPSIS	183
TUBERCULOSIS	184
MRSA	184
INFLUENZA	185
OTHER INFECTIOUS DISEASES	185
STATUS OF BIOCHIP-BASED DME DIAGNOSTICS	186
DMES	186
TABLE 76 MICROARRAY-BASED DME DIAGNOSTICS TESTS	186
WARFARIN DOSING	188
TABLE 77 WARFARIN CYP PGX DIAGNOSTICS TEST COMPETITOR SPACE	189
TABLE 78 CYP450 GENE FAMILY PHARMACOGENETIC DIAGNOSTIC GLOBAL TEST MARKET POTENTIAL, 2009 ($ MILLIONS)	192
STATUS OF BIOCHIP-BASED NEUROLOGICAL DIAGNOSTICS	192
ALZHEIMERS DISEASE	192
SCHIZOPHRENIA	193
STATUS OF BIOCHIP-BASED HEART DISEASE DIAGNOSTICS	193
CHF FAILURE	193
TABLE 79 BNP MDX TESTS FOR CHF	194
OTHER CARDIAC DIAGNOSTICS	196
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR CF	197
TABLE 80 CF BIOCHIP DIAGNOSTIC PLATFORMS	197
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR PRE- AND POST-NATAL	198
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR IMMUNE DISEASES	199
HLA TYPING TESTS	199
AUTOIMMUNE TESTING	200
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR FOOD SAFETY/QC	201
TABLE 81 BIOCHIPS STATUS IN FOOD SAFETY/QC MARKET	201

Chapter-8: BIOCHIP MARKET GROWTH DRIVING FORCES

INTRODUCTION	203
FIGURE 26 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO MICROARRAYS AND LAB ON A CHIP, 2000�2009 (NUMBER OF PUBMED CITATIONS)	203
BIOCHIP GROWTH DRIVING FORCES	204
TABLE 82 PRIMARY FORCES DRIVING OVERALL BIOCHIPS GROWTH	205
FUNDING FOR LIFE SCIENCE RESEARCH	205
TABLE 83 STIMULUS FUNDING ALLOCATED TO U.S. SCIENCE SPENDING, 2009 ($ MILLIONS)	206
FIGURE 27 NIH ANNUAL FUNDING BUDGET, 2000�2009 ($ BILLIONS)	206
LARGE-SCALE GENOMIC, PROTEOMIC, AND BIOCHIP INITIATIVES	207
TABLE 84 RESEARCH INITIATIVES DRIVING BIOCHIP GROWTH, 1999�2008	208
NEED FOR MORE EFFICIENT DRUG DISCOVERY AND DEVELOPMENT PROCESS	210
GROWTH IN PERSONALIZED MEDICINE	210
NEED FOR EARLY DETECTION OF CANCERS	211
AGING POPULATIONS	211
NEW DISCOVERIES IN GENOMICS AND PROTEOMICS	212
MINIATURIZATION OF BIOCHIPS	212
DECLINE IN GENETIC ANALYSIS COSTS	212
DISCOVERY OF GENE- AND SNP-DISEASE ASSOCIATIONS	213

Chapter-9: BIOCHIP MARKETS

GLOBAL BIOCHIP MARKET	214
TABLE 85 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS)	214
TABLE 86 GLOBAL VALUE OF BIOCHIP MARKET BY END USE, THROUGH 2014 ($ MILLIONS)	215
MICROARRAY MARKETS	216
TABLE 87 GLOBAL VALUE OF MICROARRAYS BY TYPE, THROUGH 2014 ($ MILLIONS)	216
DNA MICROARRAY MARKETS	217
DNA MICROARRAY MARKET BY APPLICATION	217
TABLE 88 GLOBAL VALUE OF DNA MICROARRAYS BY APPLICATION, THROUGH 2014 ($ MILLIONS)	217
FIGURE 28 ENTRIES TO MIRNA DATABASE, 2002�2009 (NUMBER)	219
TABLE 89 GLOBAL VALUE OF GENOTYPING DNA MICROARRAYS BY APPLICATION, THROUGH 2014 ($ MILLIONS)	220
DNA MICROARRAY MARKET BY END-USE INDUSTRY	220
TABLE 90 GLOBAL VALUE OF DNA MICROARRAYS BY END USE, THROUGH 2014 ($ MILLIONS)	221
DNA MICROARRAY MARKET BY FORMAT	222
TABLE 91 GLOBAL VALUE OF DNA MICROARRAYS BY FORMAT, THROUGH 2014 ($ MILLIONS)	222
BIOCHIPS DIAGNOSTICS MARKETS	223
BIOCHIPS DIAGNOSTIC MARKET BY APPLICATION	223
TABLE 92 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY APPLICATION, THROUGH 2014 ($ MILLIONS)	224
BIOCHIP DIAGNOSTICS MARKET BY BIOCHIP TYPE	226
TABLE 93 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2014 ($ MILLIONS)	226
CANCER DIAGNOSTICS BIOCHIPS MARKET BY INDICATION	227
TABLE 94 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY INDICATION, THROUGH 2014 ($ MILLIONS)	227
CANCER DIAGNOSTICS BIOCHIPS MARKET BY BIOCHIP TYPE	229
TABLE 95 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2014 ($ MILLIONS)	229
TABLE 96 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS	230
DIAGNOSTIC DNA MICROARRAYS MARKET BY ANALYSIS METHOD	231
TABLE 97 GLOBAL VALUE OF DIAGNOSTIC DNA MICROARRAYS BY ANALYSIS METHOD, THROUGH 2014 ($ MILLIONS)	231
DIAGNOSTIC DNA MICROARRAYS MARKET BY DIAGNOSTIC FUNCTION	233
TABLE 98 GLOBAL VALUE OF DNA MICROARRAYS DIAGNOSTICS BY DIAGNOSTIC FUNCTION, THROUGH 2014 ($ MILLIONS)	233
DIAGNOSTIC PROTEIN MICROARRAY MARKET BY TECHNOLOGY	234
TABLE 99 GLOBAL VALUE OF PROTEIN MICROARRAY DIAGNOSTICS MARKET BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)	235
PROTEIN MICROARRAYS MARKETS	236
PROTEIN MICROARRAYS MARKETS BY TECHNOLOGY	236
TABLE 100 GLOBAL VALUE OF PROTEIN MICROARRAYS BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)	236
PROTEIN MICROARRAYS MARKET BY PRODUCT FORMAT	238
TABLE 101 GLOBAL VALUE OF PROTEIN MICROARRAYS BY PRODUCT FORMAT, THROUGH 2014 ($ MILLIONS)	238
TABLE 102 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS	239
PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY	240
TABLE 103 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH 2014 ($ MILLIONS)	240
EMERGING MICROARRAYS MARKETS	241
EMERGING MICROARRAYS MARKET BY TECHNOLOGY	241
TABLE 104 GLOBAL VALUE OF EMERGING MICROARRAYS BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)	241
EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY	242
TABLE 105 GLOBAL VALUE OF EMERGING MICROARRAYS BY END-USE INDUSTRY, THROUGH 2014 ($ MILLIONS)	243
LOAC MARKETS	243
VALUE OF LOAC DEVICES BY END-USE INDUSTRY	243
TABLE 106 GLOBAL VALUE OF LOAC DEVICES BY END-USE INDUSTRY, THROUGH 2014 ($ MILLIONS)	244
LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION	248
TABLE 107 GLOBAL VALUE OF LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)	249
LOAC DIAGNOSTICS MARKET BY APPLICATION	251
TABLE 108 GLOBAL VALUE OF LOAC DEVICES DIAGNOSTICS MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)	252
BIOCHIPS GEOGRAPHIC MARKETS	254
GLOBAL VALUE OF BIOCHIPS PRODUCTS BY GEOGRAPHY	254
TABLE 109 GLOBAL VALUE OF BIOCHIP PRODUCTS BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS)	255
MICROARRAY GEOGRAPHICAL MARKETS	255
TABLE 110 GLOBAL VALUE OF DNA MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS)	256
TABLE 111 GLOBAL VALUE OF PROTEIN MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS)	257
TABLE 112 GLOBAL VALUE OF EMERGING MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS)	257
LOAC GEOGRAPHICAL MARKETS	258
TABLE 113 GLOBAL VALUE OF LOAC BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS)	258

Chapter-10: INDUSTRY DYNAMICS

INTRODUCTION	259
RECENT ACQUISITIONS IN THE BIOCHIP INDUSTRY	259
TABLE 114 KEY ACQUISITIONS IN BIOCHIP INDUSTRY, 2007�2009	260
DNA MICROARRAYS COMPETITIVE LANDSCAPE	264
TABLE 115 LEADING DNA MICROARRAY SUPPLIERS	264
SOURCES OF COMPETITIVE ADVANTAGE IN DNA MICROARRAYS	265
TABLE 116 DNA MICROARRAY AND SEQUENCING COMPETITOR STRENGTHS AND WEAKNESSES	267
NEXT GENERATION SEQUENCING COMPETITIVE LANDSCAPE	268
TABLE 117 NUMBER OF SECOND-GENERATION GENOME SEQUENCING INSTRUMENTS AT MAJOR SEQUENCING CENTERS, 2009	269
DIAGNOSTICS BIOCHIP STRATEGIC ALLIANCES	269
TABLE 118 BIOCHIP STRATEGIC ALLIANCES IN DIAGNOSTICS	270
PROTEIN MICROARRAY SUPPLIERS	272
TABLE 119 PROTEIN AND SPECIALTY MICROARRAY SUPPLIERS BY MICROARRAY TECHNOLOGY	272
LOAC COMPETITIVE LANDSCAPE	273
TABLE 120 LOAC COMPETITOR LANDSCAPE, BY COMPANY	273

Chapter-11: PATENTS

INTRODUCTION	276
BIOCHIP INDUSTRY PATENT STATUS	276
FIGURE 29 ANNUAL ISSUED DNA MICROARRAY PATENTS BY REGION, 2001�2009 (NUMBER)	277
FIGURE 30 ANNUAL ISSUED PROTEIN MICROARRAY PATENTS BY REGION, 2001�2009 (NUMBER OF PATENTS GRANTED)	278
FIGURE 31 ANNUAL ISSUED LOAC PATENTS BY GEOGRAPHY, 2001�2009 (NUMBER)	279
BIOCHIP COMPANY PATENT STATUS	280
TABLE 121 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED MICROARRAY COMPANIES (NUMBER)	280
FIGURE 32 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED MICROARRAY COMPANIES, BY REGION (NUMBER)	281
TABLE 122 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED LOAC COMPANIES (NUMBER)	283
FIGURE 33 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED LOAC COMPANIES (NUMBER)	284
BIOCHIP PATENT LITIGATION STATUS	284
TABLE 123 STATUS OF LIGITATION ISSUES IN THE BIOCHIP INDUSTRY	285
INDIVIDUAL PATENT STATUS OF SELECTED BIOCHIP COMPANIES	285
AFFYMETRIX POSITION	285
COMBIMATRIX POSITION	286
ILLUMINA POSITION	287
CALIPER POSITION	287
ROCHE-NIMBLEGEN POSITION	288

Chapter-12: COMPANY PROFILES

20/20 GENE SYSTEMS, INC.	289
ABBOTT LABORATORIES	290
ABTECH SCIENTIFIC, INC.	290
ADVANCED LIQUID LOGIC, INC.	291
AFFYMETRIX, INC.	292
TABLE 124 AFFYMETRIX STRATEGIC ALLIANCES	294
AGENDIA BV	296
TABLE 125 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE	296
AGILENT TECHNOLOGIES, INC.	298
TABLE 126 AGILENT ACQUISITIONS, 2007�2009	300
AGNITIO SCIENCE AND TECHNOLOGY	301
ALLEGRO DIAGNOSTICS, INC.	302
ALMAC GROUP, LTD.	302
APPLIED MICROARRAYS, INC.	303
ARRAYIT CORP.	305
ARRAYJET, LTD.	305
ARRAYON BIOTECHNOLOGY	306
ASPER BIOTECH	306
ASTERAND	306
AUSHON BIOSYSTEMS, INC.	307
AUTOGENOMICS, INC.	307
TABLE 127 AUTOGENOMICS MICROARRAY-BASED DIAGNOSTICS PIPELINE	308
AYANDA BIOSYSTEMS S.A.	308
BAYER AG	309
TABLE 128 CELL LYSATE MICROARRAYS VERSUS WESTERN BLOT	310
BECTON DICKINSON	311
BIACORE AB	311
BIOCARTIS S.A.	312
BIODOT, INC.	312
BIOLOC, LLC	312
BIOMICRO SYSTEMS, INC.	313
BIO-RAD LABORATORIES, INC.	313
BIOSITE, INC.	314
BIOTHERANOSTICS	315
BIOTRAY	315
BIOTROVE, INC.	316
BLUEGNOME, LTD.	316
BODITECH MED, INC.	317
CALIPER LIFE SCIENCES	317
CAPITALBIO CORP.	320
CELLECTRICON AB	322
CELLIX, LTD.	322
CELL-KINETICS, LTD.	323
CEPHEID	324
TABLE 129 COMMERCIAL STATUS OF CEPHEID CLINICAL DIAGNOSTIC TESTS BASED ON XPERT AND SMARTCYCLER PLATFORMS	325
CLAROS DIAGNOSTICS	327
CLONTECH LABORATORIES	328
COMBIMATRIX CORP.	329
TABLE 130 COMBIMATRIX DNA MICROARRAY PLATFORMS	329
TABLE 131 COMBIMATRIX DNA MICROARRAY-BASED LAUNCHED DIAGNOSTICS	330
COVENTOR, INC.	331
CRYSTAL VISION MICROSYSTEMS S.A.	331
CYCLOFLUIDIC	332
DEBIOTECH S.A.	332
DIAGENIC ASA	332
TABLE 132 DIAGENIC PATENT PORTFOLIO	334
DIAGNOSWISS S.A.	334
DNAVISION S.A.	335
DYCONEX AG	336
ECOARRAY, INC.	337
EDEL THERAPEUTICS S.A.	337
EKSIGENT TECHNOLOGIES	338
EPIGEM, LTD.	338
EXIQON A/S	339
EXONHIT THERAPEUTICS S.A.	340
TABLE 133 EXONHIT�S SPLICE-ARRAY DIAGNOSTICS PIPELINE	340
FEBIT BIOTECH GMBH	342
FLUIDIGM CORP.	342
FLUIGENT	344
FLUXION BIOSCIENCES INC.	344
GE HEALTHCARE LIFE SCIENCES, LTD.	344
GENETIX, LTD.	345
GENEWAVE S.A.S.	346
GENOMICS USA, INC.	347
GENPROBE, INC.	347
GENTEL BIOSCIENCES, INC.	348
GLYCOMINDS, LTD.	349
GRACE BIO-LABS, INC.	349
GREINER BIO-ONE GMBH	350
TABLE 134 GREINER BIO-ONE BIOCHIP-BASED DIAGNOSTICS PIPELINE	350
GYROS AB	351
HANDYLAB, INC.	352
HIGH THROUGHPUT GENOMICS, INC.	353
HOLOGIC, INC.	353
IBIDI GMBH	354
ICX TECHNOLOGIES	354
ILLUMINA, INC.	355
TABLE 135 ILLUMINA SEQUENCING TECHNOLOGY SPACE	356
IMMUCOR, INC.	357
INDEVR, INC.	358
INVERNESS MEDICAL INNOVATIONS, INC.	358
IRIS BIOTECHNOLOGIES	359
JOHNSON & JOHNSON AMIC AB	360
KINEXUS BIOINFORMATICS CORP.	361
LC SCIENCES	361
LIFE BIOSCIENCE, INC.	362
LIFE TECHNOLOGIES, INC.	363
LUMINEX	365
TABLE 136 LUMINEX MDX PIPELINE	366
TABLE 137 LUMINEX PARTNER SUMMARY	367
MICRALYNE, INC.	368
MICROCHIPS, INC.	368
MICROFLUIDIC SYSTEMS, INC.	369
MICROLIQUID	370
MICRONICS, INC.	370
MICRONIT MICROFLUIDICS	371
MICROPLUMBERS MICROSCIENCES, LLC	371
MILLIPORE	372
MOBIDIAG, LTD.	372
MOLECULAR PROFILING INSTITUTE	373
NANOSPHERE	374
NANOSURFACE BIOSCIENCES	374
NUVERA BIOSCIENCES	375
OCIMUM BIOSOLUTIONS, LTD.	376
ORIGENE TECHNOLOGIES, INC.	376
OSMETECH MOLECULAR DIAGNOSTICS	377
OSMETECH MOLECULAR DIAGNOSTICS (CONTINUED)	378
OY JURILAB, LTD.	379
PAMGENE INTERNATIONAL B.V.	380
PANAGENE, INC.	380
PATHWORK DIAGNOSTICS	381
PEPSCAN PRESTO B.V.	382
PERKINELMER	382
PERLEGEN SCIENCES, INC.	384
PROMEGA CORP.	384
PROTAGEN AG	385
QUANTRX BIOMEDICAL CORP.	386
QUEST DIAGNOSTICS	387
RANDOX LABORATORIES, LTD.	388
TABLE 138 RANDOX BIOCHIPS ASSAYS PORTFOLIO	389
ROCHE LIFE SCIENCES	390
SEQUENOM, INC.	392
SCHOTT JENA GLASS GMBH	394
SIEMENS AG	395
SIGMA ALDRICH CORP.	395
TABLE 139 SIGMA ALDRICH ACQUISITIONS, 2006�2009	396
SIGNATURE GENOMIC LABORATORIES, LLC	397
SIRS-LAB GMBH	398
SPINX TECHNOLOGIES	398
SQI DIAGNOSTIC SYSTEMS	399
STMICROELECTRONICS	400
SUPERBIOCHIP LABORATORIES	401
SURMODICS, INC.	401
TESSARAE	402
THINXXS MICROTECHNOLOGY AG	402
TRANSLUME, INC.	403
VEREDUS LABORATORIES PTE, LTD.	403
VERENIUM CORP.	404
WASATCH MICROFLUIDICS	405
WEIDMAN PLASTICS TECHNOLOGIES	405
WETWARE CONCEPTS S.R.L.	406
XCEED MOLECULAR	406
XENOPORE	407
ZEPTOSENS AG	407

Warranty Information

Number of Pages: 408

Find Similar Products by Category

Biotechnology

New Publications